Literature DB >> 21723783

Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation.

Kajsa Wing1, Tomoyuki Yamaguchi, Shimon Sakaguchi.   

Abstract

It is controversial how cytotoxic T lymphocyte antigen (CTLA)-4, a co-inhibitory molecule, contributes to immunological tolerance and negative control of immune responses. Its role as an inducer of cell-intrinsic negative signals to activated effector T cells is well documented. However, there is accumulating evidence that CTLA-4 is essential for the function of naturally occurring Foxp3(+) regulatory T (Treg) cells, which constitutively express the molecule. CTLA-4 deficiency in Foxp3(+) Treg cells indeed impairs their in vivo and in vitro suppressive function. Further, Treg cells can modulate the function of CD80- and CD86-expressing antigen-presenting cells via CTLA-4. Here we discuss how CTLA-4 expression by one T cell can influence the activation of another in a cell non-autonomous fashion and thus control immune responses.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21723783     DOI: 10.1016/j.it.2011.06.002

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  81 in total

1.  Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4.

Authors:  Sebastian Zeissig; Britt-Sabina Petersen; Michal Tomczak; Espen Melum; Emilie Huc-Claustre; Stephanie K Dougan; Jon K Laerdahl; Björn Stade; Michael Forster; Stefan Schreiber; Dascha Weir; Alan M Leichtner; Andre Franke; Richard S Blumberg
Journal:  Gut       Date:  2014-11-03       Impact factor: 23.059

2.  Re-establishing immunological self-tolerance in autoimmune disease.

Authors:  Shimon Sakaguchi; Fiona Powrie; Richard M Ransohoff
Journal:  Nat Med       Date:  2012-01-06       Impact factor: 53.440

3.  Dead on arrival: understanding the failure of CTLA4-immunoglobulin therapy in inflammatory bowel disease.

Authors:  Lloyd Mayer; Arthur Kaser; Richard S Blumberg
Journal:  Gastroenterology       Date:  2012-05-21       Impact factor: 22.682

Review 4.  Genomics of Immune Diseases and New Therapies.

Authors:  Michael Lenardo; Bernice Lo; Carrie L Lucas
Journal:  Annu Rev Immunol       Date:  2015-12-23       Impact factor: 28.527

Review 5.  The Treatment of Inflammatory Bowel Disease in Patients with Selected Primary Immunodeficiencies.

Authors:  Dror S Shouval; Matthew Kowalik; Scott B Snapper
Journal:  J Clin Immunol       Date:  2018-06-29       Impact factor: 8.317

Review 6.  Beyond sipuleucel-T: immune approaches to treating prostate cancer.

Authors:  Michael L Cheng; Lawrence Fong
Journal:  Curr Treat Options Oncol       Date:  2014-03

7.  Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis.

Authors:  Amy Dhirapong; Guo-Xiang Yang; Steven Nadler; Weici Zhang; Koichi Tsuneyama; Patrick Leung; Stuart Knechtle; Aftab A Ansari; Ross L Coppel; Fu-Tong Liu; Xiao-Song He; M Eric Gershwin
Journal:  Hepatology       Date:  2013-02       Impact factor: 17.425

Review 8.  Induced and natural regulatory T cells in the development of inflammatory bowel disease.

Authors:  Christopher G Mayne; Calvin B Williams
Journal:  Inflamm Bowel Dis       Date:  2013-07       Impact factor: 5.325

Review 9.  Epigenetic mechanisms of tumor resistance to immunotherapy.

Authors:  Natalia Arenas-Ramirez; Dilara Sahin; Onur Boyman
Journal:  Cell Mol Life Sci       Date:  2018-08-23       Impact factor: 9.261

10.  Dendritic Cell-Secreted Cytotoxic T-Lymphocyte-Associated Protein-4 Regulates the T-cell Response by Downmodulating Bystander Surface B7.

Authors:  Matthew M Halpert; Vanaja Konduri; Dan Liang; Yunyu Chen; James B Wing; Silke Paust; Jonathan M Levitt; William K Decker
Journal:  Stem Cells Dev       Date:  2016-05-02       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.